Exemplar Genetics ExeGen Cystic Fibrosis Research Model Utilized in Development of New Gene Therapy Treatments

Date and Location: 
Sioux Center, IA - September 13, 2016

Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, today announced two publication in the current issue of the Journal of Clinical Investigation (JCI) demonstrating the potential of ExeGen® CFTR MiniSwine research models to help define and develop effective gene therapies for cystic fibrosis.

Read the full release here